On 7 August 2022, Epigenic Therapeutics Co., Ltd officially announced the completion of raising over RMB 100 Million in Series angel and Pre-A round funding. This round of financing was jointly invested by Morningside Venture Capital, Kingray Capial, Trinity Innovation and TigerYeah Capital. Angel investor FountainBridge Capital is also participating. Proceeds of financing will be used to validate advances of the Company's proprietary epigenetic editing in non-human primates, expand expertise and capabilities, and sponsor early-stage clinical investigations.
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for ocular, neurodegeneration, metabolic, and rare diseases.
As the legal advisor of Epigenic Therapeutics, Llinks provided professional services for the angel round and Pre-A round financing.
Llinks Team:
Partners: Selena She, Colin Shi
Associate: Lily Yang
